Nicotinamide Riboside Chloride

• CAT Number: I008290
• CAS Number: 23111-00-4
• Molecular Formula: C11H15ClN2O5
• Molecular Weight: 290.7
• Purity: ≥95%
• Synonyms: Nicotinamide riboside; SRT647; SRT-647; SRT 647; Nicotinamide Riboside Triflate, α/β mixture;3-carbamoyl-1-((3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyridin-1-ium chloride
• Solubility: Soluble in DMSO
• Storage: 0 - 4 °C for short term, or -20 °C for long term
• IUPAC Name: 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxamide;chloride
• InChI: InChI=1S/C11H14N2O5.ClH/c12-10(17)6-2-1-3-13(4-6)11-9(16)8(15)7(5-14)18-11;/h1-4,7-9,11,14-16H,5H2,(H-,12,17);1H/t7-,8-,9-,11-;/m1./s1
• InChIKey: YABIFCKURFRPPO-IVOJBTPCSA-N
• SMILES: C1=CC(=C[N+](=C1)C2C(C(C(O2)CO)O)O)C(=O)N.[Cl-]

Nicotinamide Riboside Chloride(CAT: I008290), also known as NR and SRT647, is a pyridine-nucleoside form of vitamin B3 that acts as a precursor to nicotinamide adenine dinucleotide or NAD+. Nicotinamide Riboside prevents the aging of muscle, nerve, and melanocyte stem cells. This product is used for medical research and development.

Reference

1: Chi Y, Sauve AA. Nicotinamide riboside, a trace nutrient in foods, is a vitamin B3 with effects on energy metabolism and neuroprotection. Curr Opin Clin Nutr Metab Care. 2013 Nov;16(6):657-61. doi: 10.1097/MCO.0b013e32836510c0. Review. PubMed PMID: 24071780.
2: Bogan KL, Brenner C. Nicotinic acid, nicotinamide, and nicotinamide riboside: a molecular evaluation of NAD+ precursor vitamins in human nutrition. Annu Rev Nutr. 2008;28:115-30. doi: 10.1146/annurev.nutr.28.061807.155443. Review. PubMed PMID: 18429699.
3: Ghanta S, Grossmann RE, Brenner C. Mitochondrial protein acetylation as a cell-intrinsic, evolutionary driver of fat storage: chemical and metabolic logic of acetyl-lysine modifications. Crit Rev Biochem Mol Biol. 2013 Nov-Dec;48(6):561-74. doi: 10.3109/10409238.2013.838204. Review. PubMed PMID: 24050258; PubMed Central PMCID: PMC4113336.
4: Yang Y, Sauve AA. NAD(+) metabolism: Bioenergetics, signaling and manipulation for therapy. Biochim Biophys Acta. 2016 Dec;1864(12):1787-1800. doi: 10.1016/j.bbapap.2016.06.014. Review. PubMed PMID: 27374990.
5: Sauve AA. NAD+ and vitamin B3: from metabolism to therapies. J Pharmacol Exp Ther. 2008 Mar;324(3):883-93. doi: 10.1124/jpet.107.120758. Review. PubMed PMID: 18165311.
6: Kato M, Lin SJ. Regulation of NAD+ metabolism, signaling and compartmentalization in the yeast Saccharomyces cerevisiae. DNA Repair (Amst). 2014 Nov;23:49-58. doi: 10.1016/j.dnarep.2014.07.009. Review. PubMed PMID: 25096760; PubMed Central PMCID: PMC4254062.
7: Gerlach G, Reidl J. NAD+ utilization in Pasteurellaceae: simplification of a complex pathway. J Bacteriol. 2006 Oct;188(19):6719-27. Review. PubMed PMID: 16980474; PubMed Central PMCID: PMC1595515.
8: Srivastava S. Emerging therapeutic roles for NAD(+) metabolism in mitochondrial and age-related disorders. Clin Transl Med. 2016 Dec;5(1):25. doi: 10.1186/s40169-016-0104-7. Review. PubMed PMID: 27465020; PubMed Central PMCID: PMC4963347.
9: Handschin C. Caloric restriction and exercise /mimetics/'/': Ready for prime time? Pharmacol Res. 2016 Jan;103:158-66. doi: 10.1016/j.phrs.2015.11.009. Review. PubMed PMID: 26658171; PubMed Central PMCID: PMC4970791.
10: Ruggieri S, Orsomando G, Sorci L, Raffaelli N. Regulation of NAD biosynthetic enzymes modulates NAD-sensing processes to shape mammalian cell physiology under varying biological cues. Biochim Biophys Acta. 2015 Sep;1854(9):1138-49. doi: 10.1016/j.bbapap.2015.02.021. Review. PubMed PMID: 25770681.
11: Imai S, Guarente L. NAD+ and sirtuins in aging and disease. Trends Cell Biol. 2014 Aug;24(8):464-71. doi: 10.1016/j.tcb.2014.04.002. Review. PubMed PMID: 24786309; PubMed Central PMCID: PMC4112140.
12: Jaehme M, Slotboom DJ. Structure, function, evolution, and application of bacterial Pnu-type vitamin transporters. Biol Chem. 2015 Sep;396(9-10):955-66. doi: 10.1515/hsz-2015-0113. Review. PubMed PMID: 26352203.
13: Magni G, Di Stefano M, Orsomando G, Raffaelli N, Ruggieri S. NAD(P) biosynthesis enzymes as potential targets for selective drug design. Curr Med Chem. 2009;16(11):1372-90. Review. PubMed PMID: 19355893.
14: Mendelsohn AR, Larrick JW. Partial reversal of skeletal muscle aging by restoration of normal NAD⁺ levels. Rejuvenation Res. 2014 Feb;17(1):62-9. doi: 10.1089/rej.2014.1546. Review. PubMed PMID: 24410488.
15: Penberthy WT. Pharmacological targeting of IDO-mediated tolerance for treating autoimmune disease. Curr Drug Metab. 2007 Apr;8(3):245-66. Review. PubMed PMID: 17430113.
16: Gazzaniga F, Stebbins R, Chang SZ, McPeek MA, Brenner C. Microbial NAD metabolism: lessons from comparative genomics. Microbiol Mol Biol Rev. 2009 Sep;73(3):529-41, Table of Contents. doi: 10.1128/MMBR.00042-08. Review. PubMed PMID: 19721089; PubMed Central PMCID: PMC2738131.
17: Magni G, Amici A, Emanuelli M, Orsomando G, Raffaelli N, Ruggieri S. Enzymology of NAD+ homeostasis in man. Cell Mol Life Sci. 2004 Jan;61(1):19-34. Review. PubMed PMID: 14704851.
18: Magni G, Orsomando G, Raffelli N, Ruggieri S. Enzymology of mammalian NAD metabolism in health and disease. Front Biosci. 2008 May 1;13:6135-54. Review. PubMed PMID: 18508649.
19: Belenky P, Bogan KL, Brenner C. NAD+ metabolism in health and disease. Trends Biochem Sci. 2007 Jan;32(1):12-9. Review. Erratum in: Trends Biochem Sci. 2008 Jan;33(1):1. PubMed PMID: 17161604.
20: Niven DF, O/'Reilly T. Significance of V-factor dependency in the taxonomy of Haemophilus species and related organisms. Int J Syst Bacteriol. 1990 Jan;40(1):1-4. Review. PubMed PMID: 2145965.